In response to some bad behavior by the former Schering-Plough, French antitrust regulators have fined the Merck unit about $21 million for a campaign to thwart the introduction of a generic version of the Subutex drug that is used to treat opioid addiction. The decision was taken after reviewing a complaint filed by Arrow Generiques, which launched the generic in March 2006. The Merck (MRK) unit had previously been warned about its practices, which were described as defamation, and manipulating the market by stock saturation and offering pharmacies discounts and longer payment terms.
Help employers find you! Check out all the jobs and post your resume.
